| scholarly article | Q13442814 |
| P2093 | author name string | Diane R Mould | |
| Mohamed Badawi | |||
| Mitch A Phelps | |||
| Ashley E Rosko | |||
| Craig C Hofmeister | |||
| Douglas W Sborov | |||
| Soledad Fernandez | |||
| Ming Poi | |||
| Junan Li | |||
| Erinn M Hade | |||
| Anees Dauki | |||
| Misty Lamprecht | |||
| Yu Kyoung Cho | |||
| Donald J Irby | |||
| P2860 | cites work | Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 |
| The DNA damage response: putting checkpoints in perspective | Q28131713 | ||
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou | Q33340726 | ||
| Double-intensive therapy in high-risk multiple myeloma. | Q33352090 | ||
| Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study | Q33387332 | ||
| p53 abnormalities and potential therapeutic targeting in multiple myeloma | Q33852683 | ||
| Neutrophil kinetics in health and disease. | Q34092240 | ||
| High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma | Q34195428 | ||
| Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma | Q34283680 | ||
| Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences | Q34615102 | ||
| Pharmacogenomics: the genetics of variable drug responses | Q34976915 | ||
| Complete response after autologous stem cell transplant in multiple myeloma | Q35000475 | ||
| Clinical pharmacodynamic factors in docetaxel toxicity | Q36610962 | ||
| Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia | Q36715883 | ||
| A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT | Q36973229 | ||
| High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation | Q37030719 | ||
| XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy | Q37067591 | ||
| Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia | Q37161899 | ||
| A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. | Q37206924 | ||
| How to manage neutropenia in multiple myeloma | Q37969404 | ||
| Tumor heterogeneity and the biology of cancer invasion and metastasis | Q39759977 | ||
| Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer | Q40746556 | ||
| Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects | Q42689963 | ||
| Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed | Q42868037 | ||
| Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis | Q43564293 | ||
| Stability and performance of a population pharmacokinetic model | Q43868861 | ||
| Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer | Q43872776 | ||
| Model of chemotherapy-induced myelosuppression with parameter consistency across drugs | Q44253518 | ||
| Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor | Q44477565 | ||
| Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study | Q44943023 | ||
| Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study | Q45069647 | ||
| Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. | Q45192496 | ||
| Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma | Q46516118 | ||
| A population model for the leukopenic effect of etoposide | Q46780213 | ||
| Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients | Q46933613 | ||
| Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel-induced neutropenia in Japanese cancer patients | Q46987657 | ||
| Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia. | Q48273553 | ||
| Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients. | Q50878372 | ||
| Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial. | Q50912223 | ||
| Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer. | Q51282624 | ||
| Multiple myeloma | Q56212731 | ||
| High-risk multiple myeloma treated with high-dose melphalan | Q67718959 | ||
| A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 | ||
| Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling | Q88060567 | ||
| G-CSF improves safety when you start the day after autologous transplant in multiple myeloma | Q88075235 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| stem cell transplantation | Q65592366 | ||
| P304 | page(s) | 748-758 | |
| P577 | publication date | 2018-10-20 | |
| P1433 | published in | CPT: pharmacometrics & systems pharmacology | Q27724610 |
| P1476 | title | Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant | |
| P478 | volume | 7 |
Search more.